English
Back
Download
Need Help?
Log in to access Online Inquiry
Back to the Top

Some estimates

If Envoy’s Acclaim gets full FDA approval and achieves traction, a realistic multi-year steady-state revenue target is in the low hundreds of millions (USD) if it captures a mid single-digit market share; tens of millions is more realistic in the first 1–3 years under conservative uptake assumptions. All of this depends heavily on reimbursement, surgeon adoption, and clinical outcomes compared with entrenched competitors.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
3
1
+0
9
Translate
Report
11K Views
Comment
Sign in to post a comment
Devising Strategy. DYODD. NOTHING I said or post is financial advice but personal opinion. Accept losses and profit.
3801
Followers
4
Following
82K
Visitors
Follow